PMID- 26853848
OWN - NLM
STAT- MEDLINE
DCOM- 20161111
LR  - 20191113
IS  - 1040-8401 (Print)
IS  - 1040-8401 (Linking)
VI  - 35
IP  - 5
DP  - 2015
TI  - Acquisition and Presentation of Tumor Antigens by Dendritic Cells.
PG  - 349-64
AB  - Dendritic cells (DCs) are master regulators of the immune response and, because 
      of their peculiar features in antigen acquisition, processing, and presentation, 
      they play a critical role in activating an efficient antigenspecific T-lymphocyte 
      response against tumors. However, the DC family is composed of different cell 
      subsets, which may differently contribute to tumor-specific T-cell activation. In 
      addition to the DC subset involved, the induction of a tumor-specific adaptive 
      immune response is also dependent on DC interactions with other innate cell 
      effectors, such as natural killer cells. The different modalities by which DCs 
      can acquire tumor antigens also significantly affect antigen presentation 
      because, in addition to the presentation of tumor antigens on MHC class II upon 
      the classical exogenous antigen processing pathway, DCs are equipped to directly 
      activate cytotoxic T cells via both cross-priming and cross-dressing. Here, the 
      different forms of tumor antigen presentation by DCs are reviewed and discussed. 
      We also discuss the ways in which this novel information could be exploited in 
      the design of DC-based cancer vaccines.
FAU - Bonaccorsi, Irene
AU  - Bonaccorsi I
AD  - Laboratory of Immunology and Biotherapy, Department of Human Pathology, 
      University of Messina, Messina, Italy.
FAU - Campana, Stefania
AU  - Campana S
AD  - Laboratory of Immunology and Biotherapy, Department of Human Pathology, 
      University of Messina, Messina, Italy.
FAU - Morandi, Barbara
AU  - Morandi B
AD  - Department of Experimental Medicine (DIMES), University of Genova, Genoa, Italy; 
      Center of excellence in Biomedical Research, Centro di Eccellenza perla Ricerca 
      Biomedica (CEBR), University of Genova, Genoa, Italy.
FAU - Ferlazzo, Guido
AU  - Ferlazzo G
AD  - Laboratory of Immunology and Biotherapy, Department of Human Pathology, 
      University of Messina, Messina, Italy; Cell Therapy Program, Azienda Ospedaliera 
      Universitaria Policlinico "Gaetano Martino", Messina, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Crit Rev Immunol
JT  - Critical reviews in immunology
JID - 8914819
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Adaptive Immunity
MH  - *Antigen Presentation
MH  - Antigens, Neoplasm/immunology
MH  - Cancer Vaccines/*immunology
MH  - Cross-Priming
MH  - Dendritic Cells/*immunology/transplantation
MH  - Histocompatibility Antigens Class I/metabolism
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Neoplasms/*immunology/therapy
EDAT- 2016/02/09 06:00
MHDA- 2016/11/12 06:00
CRDT- 2016/02/09 06:00
PHST- 2016/02/09 06:00 [entrez]
PHST- 2016/02/09 06:00 [pubmed]
PHST- 2016/11/12 06:00 [medline]
AID - 3cf9880e7437a8b5,5f81b32e756edc33 [pii]
AID - 10.1615/critrevimmunol.v35.i5.10 [doi]
PST - ppublish
SO  - Crit Rev Immunol. 2015;35(5):349-64. doi: 10.1615/critrevimmunol.v35.i5.10.